Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase ...
U.S.A.I.D. workers brace for the worst. Trump halts all aid to South Africa, claiming mistreatment of white landowners.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback